πŸ‡ΊπŸ‡Έ FDA
Patent

US 12419958

Clinical formulations

granted A61KA61K31/7004A61K31/728

Quick answer

US patent 12419958 (Clinical formulations) held by Astellas Institute for Regenerative Medicine expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7004, A61K31/728, A61K33/06, A61K33/14